Abstract
Epinephrine and Norepinephrine, typically released during stress bind to nine different adrenoceptors (AR) which classically control the cardiovascular and respiratory systems. New targets were described for the many agonists and antagonists developed for these AR, as the central nervous system. During the last three decades, AR expression and action on the mammary gland/breast were extensively investigated. In the cow mammary gland, good milkability was associated with low density of β2-AR and high density of α2-AR. In the rat normal mammary gland, β-AR are expressed in the epithelial cells, alveoli, ducts, and adipocytes showing an exquisite regulation by steroid hormones and prolactin. In rat dimethylbenz(a)anthracene (DMBA) tumors, a close correlation was observed between tumor growth and β-AR concentration. β2-AR were described in numerous human cell lines and breast tumors. The action of β-adrenergic compounds on cell proliferation is contradictory. While some authors found that β-agonists significantly inhibit cancer cell proliferation and tumor growth in mice, others described a significant reduction in DNA synthesis by β-blockers. Also, positive effects of β-AR on human carcinoma cell migration have been described. α2-AR are expressed in human breast cancer and non-cancer cell lines, their stimulation being associated with increased cell proliferation. In vivo clonidine increased tumor growth and α2-adrenergic antagonists completely reversed this effect. When administered alone, rauwolscine inhibited tumor growth behaving as an inverse agonist. Therefore, the numerous adrenergic β- and α-AR agonists or antagonists could prove to be unexpected therapeutic options for mammary gland/ breast and mainly breast cancer.
Keywords: Beta-adrenoceptors, alpha-adrenoceptors, normal breast, breast cancer, mammary tumor
Current Medicinal Chemistry
Title: Adrenoceptors: Non Conventional Target for Breast Cancer?
Volume: 16 Issue: 15
Author(s): I A. Luthy, A. Bruzzone, C. Perez Pinero, L. F. Castillo, I. J. Chiesa, S. M. Vazquez and M. G. Sarappa
Affiliation:
Keywords: Beta-adrenoceptors, alpha-adrenoceptors, normal breast, breast cancer, mammary tumor
Abstract: Epinephrine and Norepinephrine, typically released during stress bind to nine different adrenoceptors (AR) which classically control the cardiovascular and respiratory systems. New targets were described for the many agonists and antagonists developed for these AR, as the central nervous system. During the last three decades, AR expression and action on the mammary gland/breast were extensively investigated. In the cow mammary gland, good milkability was associated with low density of β2-AR and high density of α2-AR. In the rat normal mammary gland, β-AR are expressed in the epithelial cells, alveoli, ducts, and adipocytes showing an exquisite regulation by steroid hormones and prolactin. In rat dimethylbenz(a)anthracene (DMBA) tumors, a close correlation was observed between tumor growth and β-AR concentration. β2-AR were described in numerous human cell lines and breast tumors. The action of β-adrenergic compounds on cell proliferation is contradictory. While some authors found that β-agonists significantly inhibit cancer cell proliferation and tumor growth in mice, others described a significant reduction in DNA synthesis by β-blockers. Also, positive effects of β-AR on human carcinoma cell migration have been described. α2-AR are expressed in human breast cancer and non-cancer cell lines, their stimulation being associated with increased cell proliferation. In vivo clonidine increased tumor growth and α2-adrenergic antagonists completely reversed this effect. When administered alone, rauwolscine inhibited tumor growth behaving as an inverse agonist. Therefore, the numerous adrenergic β- and α-AR agonists or antagonists could prove to be unexpected therapeutic options for mammary gland/ breast and mainly breast cancer.
Export Options
About this article
Cite this article as:
Luthy A. I, Bruzzone A., Pinero Perez C., Castillo F. L., Chiesa J. I., Vazquez M. S. and Sarappa G. M., Adrenoceptors: Non Conventional Target for Breast Cancer?, Current Medicinal Chemistry 2009; 16 (15) . https://dx.doi.org/10.2174/092986709788186048
DOI https://dx.doi.org/10.2174/092986709788186048 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Carbon Nanotubes: Materials for Medicinal Chemistry and Biotechnological Applications
Current Medicinal Chemistry Use of Trastuzumab for Breast Cancer: The Role of Age
Current Pharmaceutical Design Current Innovations in Laparoscopy
Current Women`s Health Reviews Celecoxib Inhibits Helicobacter pylori-induced Invasion of Gastric Cancer Cells Through an Adenine Nucleotide Translocator-Dependent Mechanism
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: Application of Novel Computational Methods in Molecular Biology, Biomedicine and Biopharmacy)
Current Bioinformatics Synthesis, Cytotoxicity Evaluation and Molecular Docking of Fluorine Containing Hexahydroquinoline-3-Carbonitrile Derivatives
Current Drug Discovery Technologies Genetic Polymorphisms of Drug Metabolizing Enzymes and Transporters: The Long Way from Bench to Bedside
Current Topics in Medicinal Chemistry GRP78 Influences Chemoresistance and Prognosis in Cancer
Current Drug Targets Natural Products Derived from Traditional Chinese Medicine as Novel Inhibitors of the Epidermal Growth Factor Receptor
Combinatorial Chemistry & High Throughput Screening Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic
Current Cancer Drug Targets The Anti-Breast Cancer Potential of Bis-Isatin Scaffolds
Current Topics in Medicinal Chemistry Insights into Targeting NEMO for Pharmacological Regulation
Current Drug Targets Repositioning the Old Fungicide Ciclopirox for New Medical Uses
Current Pharmaceutical Design Tyrosine Kinase Inhibitors: A Potential Approach to the Treatment of Hepatocellular Carcinoma
Current Pharmaceutical Design Anti-Cancer Effect of Gingerol in Cancer Prevention and Treatment
Anti-Cancer Agents in Medicinal Chemistry Self-Assembling Peptide Nanofibrous Hydrogel as a Versatile Drug Delivery Platform
Current Pharmaceutical Design Vitamin D Analogs as Anti-Carcinogenic Agents
Anti-Cancer Agents in Medicinal Chemistry Comparative Account of Quality Management and Regulatory Aspects of Products with Health Claims: Existing Approaches and Future Challenges for Probiotics and Herbal Products
Applied Clinical Research, Clinical Trials and Regulatory Affairs Epothilones: A Novel Class of Non-taxane Microtubule-stabilizing Agents
Current Pharmaceutical Design Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors
Recent Patents on Anti-Cancer Drug Discovery